Eli Lilly reported a historic 48% revenue growth in Q2 2026, driven by strong sales of Mounjaro and raised its full-year EPS guidance. Despite these results, the stock trades below its 52-week high due to concerns over U.S. price declines and acquisition charges. Analysts see modest upside, but a bullish valuation model suggests shares could reach $1,500 by late 2027 if key pipeline drugs like retatrutide succeed and regulatory approvals proceed smoothly. Risks include regulatory delays and pricing pressures on GLP-1 drugs, but the company’s strong growth and upcoming catalysts support potential multiple expansion and significant stock gains.
Eli Lilly will present mid-stage trial results for eloraTZP, a two-drug obesity treatment, on September 30. The data will show if the combo offers significantly better weight loss and tolerability than tirzepatide alone, crucial for sustaining the co...
The FDA has granted full approval to Eli Lilly's Inluriyo (imlunestrant) combined with Verzenio (abemaciclib) for treating adults with estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progressio...
